Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In the present multicentre, open‐label, prospective, phase III study, we evaluated the real‐world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3‐mg dose of NG demonstrated real‐life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoglycemia and risk of death in critically ill patients
The NICE-SUGAR Study Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204942 · Cited by 1,009
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Haugstvedt, A., Wentzel‐Larsen, T., Graue, M., Søvik, O., & Rokne, B. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02867.x · Cited by 172
Yale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88 · cited 1×
“Furthermore, the average time taken to administer NG was less than the time taken to administer injectable glucagon.(13) Injectable glucagon has been the treatment of choice for hypoglycaemia, and its efficacy is well established(1); however, injectable glucagon requires reconstitution and injection.”
BackgroundSelf-citation
Cited by
Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00845-7 · Cited by 32
Self-citationMatsuhisa, M., Takita, Y., Nasu, R., Nagai, Y., Ohwaki, K., & Nagashima, H. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14019 · Cited by 27
“As expected, NG-treated participants had more nasal and non-nasal symptoms, which are considered administration route-related (Table 1).(9,12) Limitations of the present study include lack of study blinding, which means that the possibility of bias cannot be completely ruled out, particularly for safety evaluation inc…”
BackgroundPontiroli, A. E., & Tagliabue, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01483-y · Cited by 25
Metadata
- Authors
- Seaquist, E. R., Dulude, H., Zhang, X. M., Rabasa‐Lhoret, R., Tsoukas, G. M., Conway, J. R., Weisnagel, S. J., Gerety, G., Woo, V. C., Zhang, S., Carballo, D., Pradhan, S., Piché, C. A., & Guzman, C. B.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-03-22
- Volume
- 20
- Issue
- 5
- Pages
- 1316-1320
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2789501252
- Cited by
- 54
- References
- 7
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.